Business Context and Reporting Period
This Form 8-K filing by BridgeBio Pharma, Inc. (BBIO) reports a change in corporate officers effective December 31, 2020, and January 1, 2021. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Yi Ching Yau resigned as Principal Accounting Officer effective December 31, 2020. She continues in her role as Chief Accounting Officer.
- Appointment: Brian C. Stephenson, Ph.D., CFA, was designated as the new Principal Accounting Officer effective January 1, 2021. Dr. Stephenson currently serves as the Company's Chief Financial Officer and Principal Financial Officer.
Management Commentary and Risks
Dr. Stephenson will oversee the Company's accounting matters. He has served as CFO since October 2018 and brings prior experience from Capital IP Investment Partners, Leerink Partners, and McKinsey & Company. The filing states that Dr. Stephenson is not receiving additional compensation for this designation and that there are no family relationships or undisclosed interests requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Confirm the effective dates of the Principal Accounting Officer transition (Dec 31, 2020, and Jan 1, 2021).
- Verify that no additional compensation was provided to Dr. Stephenson for the new role.
- Review Dr. Stephenson's background as CFO since October 2018 to assess continuity in financial oversight.
- Note that this filing contains no financial results; refer to the most recent 10-K or 10-Q for fiscal metrics.